Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL, a Pediatric Oncology Group (POG) study

Leukemia

Volumn 13, Issue 11, 1999, Pages 1696-1707

  Pullen, J ^a   Shuster, J J ^b   Link, M ^c   Borowitz, M ^d   Amylon, M ^c   Carroll, A J ^e   Land, V ^f   Look, A T ^g   McIntyre, B ^a   Camitta, B ^h  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b Pediat Oncol Grp Stat Office   (United States)

^c STANFORD UNIVERSITY   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Pediat Oncol Grp Operations Off   (United States)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h Midwest Children's Cancer Center   (United States)

Author keywords

Acute lymphocytic leukemia; B precursor; Childhood; Prognostic factors; T cell

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; B CELL LEUKEMIA; CANCER STAGING; CHILD; CHILDHOOD CANCER; COMPARATIVE STUDY; DIPLOIDY; FEMALE; GENDER; GENE TRANSLOCATION; HIGH RISK POPULATION; HUMAN; IMMUNOPHENOTYPING; LABORATORY; LEUKEMIA CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RACE; STEM CELL; T CELL LEUKEMIA;

EID: 0032747903     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401555     Document Type: Article

References (47)

1. Sallan SE, Ritz J, Pesando J, Gelber R, O'Brien C, Hitchcock S, Coral F, Schlossman SF. Cell surface antigens: Prognostic implications in childhood acute lymphoblastic leukemia. Blood 1980; 55: 395-402.
2. Greaves MF, lanossy G, Peto J, Humphrey K. Immunologically defined subclasses of acute lymphoblastic leukemia in children: their relationship to presentation features and prognosis. Br J Haematol 1981; 48: 179-197.
3. Pullen DJ, Boyett JM, Crist WM, Falletta JM, Roper M, Dowell B, van Eys J, lackson JF, Humphrey GB, Metzgar RS, Cooper MD. Pediatric Oncology Group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: influence on treatment response. Ann NY Acad Sci 1984; 428: 26-48.
4. Crist WM, Grossi CE, Pullen DJ, Cooper MD. Immunologic markers in childhood acute lymphocytic leukemia. Semin Oncol 1985; 12: 105-121.
5. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M, Mirro J Jr, Ochs JS, Look AT, Williams DL, Murphy SB, Dahl GV, Kalwinski DK, Evans WE, Kun LE, Simone JV, Crist WM. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66.
6. Crist W, Shuster J, Look T, Borowitz M, Behm F, Bowman P, Frankel L, Pullen J, Krance R, Steuber P, Camitta B, Amylon M, Link M, Land V. Current results of studies of immunophenotype-, age-, and leukocyte-based therapy for children with acute lymphoblastic leukemia. A Pediatric Oncology Group study. Leukemia 1992; 6: 162-167.
7. Pui C-H, Behrn FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993; 82: 343-362.
8. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui C-H, Pullen J, Reaman G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14; 18-24.
9. Aricò M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E, Zanesco L, Rondelli R, Pession A, Masera G for the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. Cancer 1995; 75: 1684-1693.
10. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994; 12: 740-747.
11. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
12. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, Camitta B, Murphy SB. Intensive high dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia 1999; 13: 335-342.
13. Uckun FM, Sensel MG, Sun L, Steinherz PG, Trigg ME, Heerema NA, Sather HN, Reaman GH, Gaynon PS. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91: 735-746.
14. Niehues T, Kapaun P, Harms DO, Burdach S, Kramm C, Körholz D, Janka-Schaub G, Göbel U. A classification based on T-cell selection-related phenotypes identities a subgroup of childhood T-ALL with favorable outcome in the COALL studies. Leukemia 1999; 13: 614-617.
15. Clavell LA, Gelber RD, Cohen HJ, Hitchcock-Bryan S, Cassady JR, Tarbell NJ, Blattner SR, Tantravahi R. Leavitt P, Sallan SE. Four agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. New Engl J Med 1986; 315: 657-663.
16. Shuster JJ, Falletta JM, Pullen J, Crist WM, Humphrey GB, Dowell BL, Wharam MD, Borowitz M. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1990; 75: 166-173.
17. Pui C-H. Childhood leukemias. New Engl J Med 1995; 332: 1618-1630.
18. Uckun FM, Reaman G, Steinherz PG, Arthur DC, Sather H, Trigg M, Tubergen D, Gaynon P. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group study. Leuk Lymphoma 1996; 24: 57-70.
19. Chessels JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Resarch Council Working Party on Childhood Leukemia. Lancet 1995; 345: 143-148,
20. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman PS, Miller DR, Reaman GH, Sather HN, Hammond GD. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group study CCC-193P. Am J Ped Hematol/Oncol 1988; 10: 42-50.
21. Cherlow JM, Steinherz PG, Sather HN, Gaynon PS, Grossman NJ, Kersey JH, Johnstone HS, Breneman JC, Trigg ME, Hammond GD. The role of radiation therapy in the treatment of acute lymphoblastic leukemia with lymphomalous presentation: a report from the Children's Cancer Group. Int J Radiat Oncol Biol Phys 1993; 27: 1001-1009.
22. Pullen DJ, Sullivan MP, Falletta JM, Boyett JM, Humphrey GB, Starling KA, Land VJ, Dyment PG, Vats T, Duncan MH. Modified LSA2-L2 treatment in 53 children with E-rosette positive T-cell leukemia: results and prognostic factors, (a Pediatric Oncology Group study.) Blood 1982; 60: 1159-1168.
23. Falletta JM, Shuster JJ, Crist WM, Pullen DJ, Borowitz MJ, Wharam M, Patterson R, Foreman E, Vietti TJ. Different patterns of relapse associated with three intensive treatment regimens for pediatric Erosette positive T-cell leukemia: a Pediatric Oncology Group study. Leukemia 1992; 6: 541-546.
24. Crist W, Boyett J, Pullen J, van Eys J, Vietti T. Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents: a Pediatric Oncology Group review. Med Pediatr Oncol 1986; 14: 135-139.
25. Ludwig W-D, Teichmann JV, Sperling C, Komischke B, Ritter J, Reiter A, Odenwald E, Sauter S, Riehm H. Incidence, clinical characteristics, and prognostic significance of immunological subtypes in childhood acute lymphoblastic leukemia: experience of therapy studies ALL-BFM 83 and 86. Klin Pädiatr 1990; 202: 243-252.
26. Trueworthy R, Shuster J, Look T, Crist W, Borowitz M, Carroll A, Frankel L, Harris M, Wagner H, Haggard M, Mosijczuk A, Pullen I, Steuber P, Land V. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol 1992; 10: 606-613.
27. Borowitz MJ, Carroll AJ, Shuster JJ, Look AT, Behm FG, Pullen DJ, Land VJ, Steuber P, Crist WM. Use of clinical and laboratory features to define prognostic subgroups in B-precursor acute lymphoblastic leukemia: experience of the Pediatric Oncology Group. In: WD Ludwig, E Thiel (eds). Recent Results in Cancer Research, vol. 131. Springer-Verlag: Berlin, Heidelberg, 1993, pp 257-267.
28. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ, Look AT, Mahoney D, Ragab A, Pullen DJ, Land VJ. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13). A Pediatric Oncology Group study. Blood 1990; 76: 117-122.
29. Koehler M, Behm FG, Shuster J, Crist W, Borowitz M, Look AT, Head D, Carroll AJ, Land V, Steuber P, Pullen DJ. Transitional pre-B-cell acute lymphoblastic leukemia of childhood is associated with favorable prognostic clinical features and an excellent outcome: a Pediatric Oncology Group study. Leukemia 1993; 7: 2064-2068.
30. Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J, Link M, Head D, Carroll A, Berard C, Murphy S. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a Pediatric Oncology Group study. J Clin Oncol 1996; 14: 1252-1261.
31. ISCN (1985). An International System for Human Cytogenetic Nomenclature. Harnden DG, Klinger HP (eds). S Karger: Basel, 1985.
32. ISCN (1991). Guidelines for Cancer Cytogenetics, Supplement to an International System for Human Cytogenetic Nomenclature. Mitelman F (ed). S Karger: Basel, 1991.
33. Ludwig W-D, Harbott J, Bartram CR, Komischke B, Sperling C, Teichmann JV, Seibt-Jung H, Notter M, Odenwald E, Nehmer A, Thiel E, Riehm H. Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: experience of the BFM study 86. In: WD Ludwig, E Thiel (eds). Recent Results in Cancer Research, vol. 131. Springer-Verlag: Berlin, Heidelberg, 1993, pp 269-282.
34. Peto R, Armitage P, Brewlow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
35. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972; 34: 187-220.
36. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
37. Pui C-H, Behm FG, Singh B, Schell MJ, Williams DL, Rivera GK, Kalwinsky DK, Sandlund JT, Crist WM, Raimondi SC. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990; 75: 174-179.
38. Garand R, Vannier JP, Béné MC, Faure G, Favre M, Bernard A and the Groupe d'Etude Immunologique des Leucémies. Comparison of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. Leukemia 1990; 4: 739-744.
39. Uckun FM, Steinherz PG, Sather H, Trigg M, Arthur D, Tubergen D, Gaynon P, Reaman G. CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 1996; 88: 4288-4295.
40. Crist W, Pullen J, Boyett J, Falletta J, van Eys J, Borowitz M, Jackson J, Dowell B, Russell C, Quddus F, Ragab A, Vietti T. Acute lymphoid leukemia in adolescents: clinical and biologic features predict a poor prognosis - a Pediatric Oncology Group study. J Clin Oncol 1988; 6: 34-43.
41. Dowell BL, Borowitz MJ, Boyett JM, Pullen DJ, Crist WM, Quddus FF, Russell EC, Falletta JM, Metzgar RS. Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group study. Cancer 1987; 59: 2020-2026.
42. Schrappe M, Sperling C, Reiter A, Ratei R, Zimmerman M, Goetz N, Riehm H, Ludwig W-D. In vivo sensitivity of childhood T-cell ALL is the most relevant prognostic marker independent of maturational stage. Blood 1998; 92: 397a.
43. Pui C-H, Carroll AJ, Head D, Raimondi SC, Shuster JJ, Crist WM, Link MP, Borowitz MJ, Behm FG, Land VJ, Nash MB, Pullen DJ, Look AT. Near-triploid and near-tetraploid acute lymphoblastic leukemia of childhood. Blood 1990; 76: 590-596.
44. Crist WM, Shuster JJ, Falletta J, Pullen DJ, Berard CW, Vietti TJ, Alvarado CS, Roper MA, Prasthofer E, Grossi CE. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group study. Blood 1988; 72: 1891-1897.
45. European Group for the Immunological Characterization of Leukemias (EGIL): Bené MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB. Proposals for the immunological classification of acute leukemias. Leukemia 1995; 9: 1783-1786.
46. Uckun FM, Gaynon PS, Sensel MG, Nachman J, Trigg ME, Steinherz PG, Hutchinson R, Bostrom BC, Sather HN, Reaman GH. Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study. J Clin Oncol 1997; 15: 2214-2221.
47. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Chappell R, Hammond D, Bleyer WA. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the Children's Cancer Group. J Clin Oncol 1996; 14: 389-398.